ASCO 2025 Press Releases Johnson & Johnson Leads with First PARP Inhibitor Combo to Improve Efficacy in Patients with HRR-altered mCSPC ImmunityBio Receives FDA Expanded Access Authorization for ...
(UroToday.com) The 2025 SUO annual meeting featured the Huggins Medal Lecture and presentation by this year’s recipient, Dr. Peter Carroll, discussing “What I did and What I am Doing”. Important ...
Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Long-term Survival in Men with Gleason Score 9-10 Treated ...
Zachary Klaassen speaks with Jie Luo about his Prostate Cancer Foundation Young Investigator Award work on androgen receptor enhanceosomes in prostate cancer. Dr. Luo explains that enhanceosomes are ...
This Guideline covers the surgical management of patients with ureteral and/or kidney stones and is intended for clinicians evaluating and managing patients with this disease. The summary presented ...
In patients with muscle-invasive bladder cancer (MIBC) managed with radical cystectomy, the perioperative systemic therapy landscape is transforming rapidly. Historically, cisplatin-eligible patients ...
role of Blue Light Cystoscopy in identifying tumors undetected by WLC, Bladder Cancer, Blue Light Cystoscopy for non-muscle-invasive bladder cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback